Brian Slingerland co-founded and was the CEO of Stemcentrx, which discovered a number of novel cancer targets and developed in-house target validation, GMP manufacturing and clinical development capabilities. The company had target and platform-specific partnerships with Pfizer and Bristol Myers Squibb, and was acquired by AbbVie. Prior to Stemcentrx, Brian co-founded Qatalyst Partners which became a leading strategic and transactional advisor to technology companies. Brian’s early career was spent with Goldman Sachs and Credit Suisse advising companies on private financings, IPOs, partnerships, mergers & acquisitions.
